

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/37477Serial No.
09/880,417

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Andrei V. Gudkov et al.Filing Date
June 13, 2001Group
16145
JUL 17 2001
TECH CENTER 1600/2000
07 17 2001
RECEIVED

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<i>Q</i>		5,919,808	07/06/99	Petrie et al.	514	372	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
<i>Q</i>		WO96/28454	19.09.96	PCT	C07D	513/04	Abstract	
<i>Y</i>		WO98/17267	30.04.98	PCT	A61K	31/165		
<i>Q</i>		11029475	02.02.99	Japan	A61K	31/425	Abstract	
<i>Q</i>		7291976	07.11.95	Japan	C07D	513/04	Abstract	
<i>Q</i>		11106340	20.04.99	Japan	A61K	31/425	Abstract	
<i>Q</i>		0 430 334	05.06.91	EPO	C07D	277/40		

EXAMINER <i>Q</i>	DATE CONSIDERED <i>9/26/02</i>
-------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/37477Serial No.
09/880,440

OCT 15 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Andrei V. Gudkov et al.Filing Date
June 13, 2001Group
1614

TECH CENTER 1600/2000

Oct 17 2001

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Q	Komarova et al., "Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53," <i>Oncogene</i> , 17, pp. 1089-1096 (1998).
Q	Andreani et al., "Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase," <i>Journal of Medicinal Chemistry</i> , Vol. 38, pp. 1090-1097 (1995).
Q	Balse et al., "Condensed tetrahydrobenzothiazoles: Part III--synthesis fo 2-aryl-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazoles & 1,2,3,4-tetrahydrobenzimidazo[2,1-b]benzothiazoles & their 4/5 carbethoxy derivatives," <i>Indian Journal of Chemistry</i> , Vol. 19B, pp. 263-265 (1980).
Q	Singh et al., "Heterocyclic systems containing bridgehead nitrogen atom: Part XXV--Syntheses of imidazo[2,1-b]benzothiazoles & quinoxalino[2,3:4',5']-imidazo[2',1'-b]benzothiazoles," <i>Indian J. Chem.</i> , Vol. 14B, pp. 997-998 (1976).
Q	Naito et al., "Syntehsis of 2-phenylimidazo[2,1-b]benzothiazole derivatives as modulators of multidrug resistance for tumor cells," <i>J. Heterocyclic Chem.</i> , 34, pp. 1763-1767 (1997).
Q	Kochergin et al., "Action of α -halo ketones on 2-mercaptopimidazoles," <i>J. Gen. Chem. U.S.S.R.</i> , 26, pp. 483-489 (1980).
Q	P.G. Komarov et al., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy, <i>Science</i> , 285, pp. 1733-1737 (1999).
Q	K.K. Bhargava et al., Tetramisole analogues as inhibitors of alkaline phosphatase, an enzyme involved in the resistance of neoplastic cells to 6-thiopurines, <i>Journal of Medicinal Chemistry</i> , 20, No. 4, pp. 563-566 (1977).
Q	C.L. Baird et al., Synthesis, characterization and antitumor activity of platinum triamine complexes containing imidazothiazole ligands, <i>Inorganica Chimica Acta</i> , 256, pp. 253-262 (1997).

EXAMINER

DATE CONSIDERED

9/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/37477Serial No.
09/880,4Applicant
Andrei V. Gudkov et al.Filing Date
June 13, 2001Group
1614

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OCT 17 2001

RECEIVED
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Q	A. Singh et al., Heterocyclic systems containing bridgehead nitrogen atom: Part XXV--syntheses of imidazo[2,1-β]benzothiazoles & quinoxalino[2,3:4'5']imidazo[2',1'-β]benzothiazoles, <i>Indian J. Chem.</i> , 14B, pp. 997-998 (1976).
9	S. Tasaka et al., Synthesis of 2-phenylimidazo[2,1-β]benzothiazole derivatives as modulators of multidrug resistance for tumor cells, <i>J. Heterocyclic Chemistry</i> , 34, pp. 1763-1767 (1997).
Q	S.N. Sawhney et al., Synthesis & anti-inflammatory activity of some 6-alkyl- or aryl-imidazo[2,1-β]thiazole-3-acetic acids, <i>Indian J. Chem.</i> , 16B, pp. 523-524 (1978).
9	E.A. Komarova et al., Could p53 be a target for therapeutic suppression?, <i>Seminars in Cancer Biology</i> , 8, No. 5, pp. 389-400 (1998).
9	R.J.C. Steele et al., The p53 tumour suppressor gene, <i>British Journal of Surgery</i> , 85, pp. 1460-1467 (1998).
9	E.A. Komarova et al., Transgenic mice with p53-responsive <i>lacZ</i> :p53 activity varies dramatically during normal development and determines radiation and drug sensitivity <i>in vivo</i> , <i>The EMBO Journal</i> , 16, No. 6, pp. 1391-1400 (1997).
Q	Singh et al., <i>Indian J. Chem.</i> , Sect. B, 14B(12), 997-8 (1976).

EXAMINER

DATE CONSIDERED

9/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.